Deal for further 100 million doses of Pfizer and BioNTech jab to go to EU
Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) are to supply an additional 100 million doses of Comirnaty, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021.
The announcement is a result of the European Commission’s (EC) decision to exercise its option to buy an additional 100 million doses under its expanded Advanced Purchase Agreement signed in February. This brings the total number of doses to be delivered to the EU to 600 million.
"The largest cumulative supply agreement for Comirnaty that we have agreed to date globally"Although there have been serious but treatable allergic reactions in a very small number of people given the Pfizer-BioNTech vaccine, more serious concerns over blood clots have impacted the rollout of the jabs from AstraZeneca (LSE: AZN) and Johnson & Johnson (NYSE: JNJ).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze